Celularity Inc. (CELU)

Market Cap	50.94M -51.6%
Revenue (ttm)	26.55M -51.0%
Net Income	-91.80M
EPS	-3.59
Shares Out	28.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	273,719
Open	1.880
Previous Close	1.880
Day's Range	1.760 - 1.960
52-Week Range	0.560 - 3.154
Beta	0.80
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 15, 2026

About CELU

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn’s disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn’s) and degenerative disease; and PDA-002 for treating multip...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 115
• Stock Exchange: NASDAQ
• Ticker Symbol: CELU
• Website: https://www.celularity.com

Financial Performance

In 2025, Celularity's revenue was $26.55 million, a decrease of -51.03% compared to the previous year's $54.22 million. Losses were -$91.80 million, 58.6% more than in 2024.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 2, 2026

Data Sources Report a data error